BioCentury | Jan 11, 2016

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
BC Week In Review | Apr 13, 2015
Company News

Merck & Co. Inc, Akorn deal

InSite Vision Inc. (OTCBB:INSV, Alameda, Calif.) settled a lawsuit against Mylan N.V. (NASDAQ:MYL, Canonsburg, Pa.) concerning Mylan’s ANDA for 1% azithromycin ophthalmic solution. The settlement triggers an increase to 9% from 8% in the royalty...
BC Week In Review | Feb 9, 2015
Company News

InSite, Nicox deal

InSite granted Nicox exclusive rights to develop, manufacture and commercialize AzaSite , BromSite and AzaSite Xtra in Europe, the Middle East and Africa. Nicox expects to submit MAAs for AzaSite and BromSite in 1Q16 and launch...
BC Week In Review | Sep 8, 2014
Company News

InSite, Inspire deal

In June, Akorn Inc. (NASDAQ:AKRX, Lake Forest, Ill.) paid InSite $6 million in exchange for a lower royalty rate that it pays InSite on net sales of ophthalmic product AzaSite azithromycin in North America. Last...
BC Week In Review | Jun 16, 2014
Company News

InSite, Senju deal

InSite granted Senju an exclusive, Japanese license to develop and commercialize InSite's azithromycin ophthalmic solutions using DuraSite sustained drug delivery technology, including macrolide antibiotics AzaSite 1% azithromycin and AzaSite Xtra 2% azithromycin ( ISV-405 ). AzaSite...
BC Week In Review | Nov 25, 2013
Company News

Akorn, Merck sales and marketing update

Akorn will acquire U.S. rights to ophthalmic products AzaSite 1% azithromycin, Cosopt and Cosopt PF dorzolamide/timolol maleate from Merck's Inspire Pharmaceuticals Inc. subsidiary for $52.8 million in cash. Merck will supply the products to Akorn...
BC Week In Review | Nov 18, 2013
Company News

InSite, Merck, Novartis, Pfizer ophthalmic news

Novartis' Sandoz Inc. generics unit filed an appeal asking the U.S. Court of Appeals for the Federal Circuit to rehear a 2011 patent infringement suit regarding AzaSite 1% azithromycin ophthalmic solution. In October, the U.S....
BC Week In Review | Oct 14, 2013
Company News

InSite Vision Inc, Merck, Novartis, Pfizer ophthalmic news

The U.S. District Court for the District of New Jersey ruled in favor of Merck, Pfizer and InSite in InSite Vision Inc. et al. vs. Sandoz Inc. et al., a 2011 patent infringement suit against...
BioCentury | Oct 7, 2013

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
BC Week In Review | Jul 29, 2013
Clinical News

AzaSite Plus: Phase III data

Top-line data from the double-blind, U.S. Phase III DOUBle trial in 907 patients with moderate to severe blepharitis showed that AzaSite Plus and DexaSite each missed the primary endpoint of complete resolution of all clinical...
Items per page:
1 - 10 of 100